Table 1.
Chronologic assessment and therapy of patient.
| Date | Chemotherapy | Biologic therapy | Y90 treatment | Chest CT | Abdomen CT | Abdominal MRI |
|---|---|---|---|---|---|---|
| 06/07/13 | — | — | — | Lung mass in the right lower lobe | Multiple liver lesions | — |
|
| ||||||
| 06/17/13 | FOLFIRI | Aflibercept | — | — | — | — |
|
| ||||||
| 07/03/13 | — | — | Right lobe radio embolization | — | — | — |
|
| ||||||
| 7/15/13 | FOLFIRI | Held due to risk of bleeding from radioembolization | — | — | — | — |
|
| ||||||
| 08/08/13 | — | — | Right and left lobe radio embolization | — | — | — |
|
| ||||||
| 08/19/13 | FOLFIRI | Aflibercept resumed | — | — | — | — |
|
| ||||||
| 09/02/13 | FOLFIRI | Aflibercept | — | — | — | — |
|
| ||||||
| 09/20/13 | FOLFIRI | Aflibercept | — | Stable pulmonary nodules |
Stable liver hypodensities | Interval decrease in size of the hepatic masses in the right lobe of the liver |
|
| ||||||
| 10/07/13 | FOLFIRI | Aflibercept | — | — | — | — |
|
| ||||||
| 10/21/13 | Omission of 5-FU due to fatigue and dehydration but continued with irinotecan | Aflibercept | — | — | — — |
— — |
|
| ||||||
| 11/18/13 | Irinotecan | Aflibercept held due to worsening fatigue | — | — | — | — |
|
| ||||||
| 11/25/13 | Irinotecan | Held Aflibercept due to fatigue | — | — | — | — |
|
| ||||||
| 12/2/13 | Irinotecan | Aflibercept resumed at 50% reduced dose | — | — | — | — |
|
| ||||||
| 12/16/13 | Irinotecan | Aflibercept continued at 50% reduced dose | — | — | — | — |
|
| ||||||
| 12/30/13 | Chemotherapy held due to G3 fatigue and G3 diarrhea | Chemotherapy held due to G3 fatigue and G3 diarrhea | — | Interval increase of lung nodules (Progression) | Stable disease within the liver, interval development of small abdominal ascites (from trace on prior imaging) and slightly nodular contour to the liver, reflecting treatment related effects of prior radioembolization and chemotherapy. | — |
|
| ||||||
| 1/21/14 | Started on a phase I study with a novel anti-VEGFR3 antibody | — | — | — | — | — |